In Brief: Cholestech
This article was originally published in The Gray Sheet
Executive SummaryCholestech: Files petition with the Centers for Disease Control and Prevention to reclassify the firm's total cholesterol, HDL cholesterol, triglycerides and glucose tests from the "moderately complex" to "waived" category under provisions of the Clinical Laboratory Improvements Amendments of 1988. CDC recently lifted its moratorium on processing in vitro diagnostic test waiver requests ("The Gray Sheet" Jan. 30, p. 4)...
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.
How do notified bodies ensure that their personnel, and the teams they allocate for conformity assessment of medical devices, have the precise knowledge and expertise needed? A new EU document gives guidance on this.